CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CRL - US1598641074 - Common Stock
199.48 USD
-2.5 (-1.24%)
199.48 USD
0 (0%)
CRL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. CRL has only an average score on both its financial health and profitability. CRL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
CRL had positive earnings in the past year.
In the past year CRL had a positive cash flow from operations.
In the past 5 years CRL has always been profitable.
CRL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.11%, CRL is in line with its industry, outperforming 57.89% of the companies in the same industry.
CRL's Return On Equity of -2.45% is in line compared to the rest of the industry. CRL outperforms 59.65% of its industry peers.
CRL has a Return On Invested Capital of 5.84%. This is in the better half of the industry: CRL outperforms 73.68% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CRL is significantly below the industry average of 13.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| ROIC | 5.84% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
In the last couple of years the Profit Margin of CRL has declined.
The Operating Margin of CRL (11.73%) is better than 71.93% of its industry peers.
In the last couple of years the Operating Margin of CRL has remained more or less at the same level.
CRL has a Gross Margin of 34.68%. This is in the lower half of the industry: CRL underperforms 63.16% of its industry peers.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.73% | ||
| PM (TTM) | N/A | ||
| GM | 34.68% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CRL is destroying value.
Compared to 1 year ago, CRL has less shares outstanding
CRL has more shares outstanding than it did 5 years ago.
CRL has a better debt/assets ratio than last year.
2.2 Solvency
CRL has an Altman-Z score of 2.60. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.60, CRL is doing good in the industry, outperforming 64.91% of the companies in the same industry.
CRL has a debt to FCF ratio of 4.02. This is a neutral value as CRL would need 4.02 years to pay back of all of its debts.
CRL's Debt to FCF ratio of 4.02 is fine compared to the rest of the industry. CRL outperforms 75.44% of its industry peers.
CRL has a Debt/Equity ratio of 0.64. This is a neutral value indicating CRL is somewhat dependend on debt financing.
CRL's Debt to Equity ratio of 0.64 is on the low side compared to the rest of the industry. CRL is outperformed by 71.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 4.02 | ||
| Altman-Z | 2.6 |
ROIC/WACC0.56
WACC10.49%
2.3 Liquidity
CRL has a Current Ratio of 1.37. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.37, CRL is not doing good in the industry: 80.70% of the companies in the same industry are doing better.
A Quick Ratio of 1.10 indicates that CRL should not have too much problems paying its short term obligations.
CRL has a Quick ratio of 1.10. This is in the lower half of the industry: CRL underperforms 75.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.25%.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.93% on average per year.
The Revenue has decreased by -0.92% in the past year.
The Revenue has been growing by 9.09% on average over the past years. This is quite good.
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
3.2 Future
Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 6.83% on average per year.
Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 2.25% on average per year.
EPS Next Y0.17%
EPS Next 2Y3.1%
EPS Next 3Y5.39%
EPS Next 5Y6.83%
Revenue Next Year-0.56%
Revenue Next 2Y0.55%
Revenue Next 3Y1.91%
Revenue Next 5Y2.25%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CRL is valuated rather expensively with a Price/Earnings ratio of 18.91.
CRL's Price/Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 92.98% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. CRL is valued slightly cheaper when compared to this.
CRL is valuated rather expensively with a Price/Forward Earnings ratio of 18.18.
Based on the Price/Forward Earnings ratio, CRL is valued cheaper than 89.47% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.13, CRL is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.91 | ||
| Fwd PE | 18.18 |
4.2 Price Multiples
CRL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CRL is cheaper than 92.98% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CRL is valued cheaper than 89.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.06 | ||
| EV/EBITDA | 13.12 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CRL does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)113.73
PEG (5Y)2.12
EPS Next 2Y3.1%
EPS Next 3Y5.39%
5. Dividend
5.1 Amount
No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
199.48
-2.5 (-1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners106.76%
Inst Owner Change-7.93%
Ins Owners0.89%
Ins Owner Change0.17%
Market Cap9.82B
Revenue(TTM)4.02B
Net Income(TTM)-83.48M
Analysts77.27
Price Target201.38 (0.95%)
Short Float %4.95%
Short Ratio2.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.28%
Min EPS beat(2)2.88%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)10.51%
Min EPS beat(4)2.88%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.19%
EPS beat(12)12
Avg EPS beat(12)8.5%
EPS beat(16)16
Avg EPS beat(16)6.77%
Revenue beat(2)2
Avg Revenue beat(2)2.06%
Min Revenue beat(2)0.38%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.12%
Min Revenue beat(4)0.38%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.53%
Revenue beat(12)10
Avg Revenue beat(12)1.83%
Revenue beat(16)12
Avg Revenue beat(16)1.25%
PT rev (1m)4.41%
PT rev (3m)10.59%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)-2.1%
EPS NY rev (1m)0.47%
EPS NY rev (3m)0.44%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)0.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.91 | ||
| Fwd PE | 18.18 | ||
| P/S | 2.44 | ||
| P/FCF | 18.06 | ||
| P/OCF | 13.1 | ||
| P/B | 2.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.12 |
EPS(TTM)10.55
EY5.29%
EPS(NY)10.97
Fwd EY5.5%
FCF(TTM)11.05
FCFY5.54%
OCF(TTM)15.23
OCFY7.63%
SpS81.75
BVpS69.19
TBVpS-1.79
PEG (NY)113.73
PEG (5Y)2.12
Graham Number128.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| ROCE | 7.39% | ||
| ROIC | 5.84% | ||
| ROICexc | 6.03% | ||
| ROICexgc | 13.86% | ||
| OM | 11.73% | ||
| PM (TTM) | N/A | ||
| GM | 34.68% | ||
| FCFM | 13.51% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexgc growth 3Y-14.69%
ROICexgc growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 4.02 | ||
| Debt/EBITDA | 2.43 | ||
| Cap/Depr | 48.19% | ||
| Cap/Sales | 5.12% | ||
| Interest Coverage | 4.36 | ||
| Cash Conversion | 83.34% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.6 |
F-Score4
WACC10.49%
ROIC/WACC0.56
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
EPS Next Y0.17%
EPS Next 2Y3.1%
EPS Next 3Y5.39%
EPS Next 5Y6.83%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
Revenue Next Year-0.56%
Revenue Next 2Y0.55%
Revenue Next 3Y1.91%
Revenue Next 5Y2.25%
EBIT growth 1Y-22.72%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year29.81%
EBIT Next 3Y11.7%
EBIT Next 5Y9.91%
FCF growth 1Y47.54%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y7.42%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%
CHARLES RIVER LABORATORIES / CRL FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?
ChartMill assigns a valuation rating of 5 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for CRL stock?
The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 0.17% in the next year.